| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 03/21/2002 | WO2002022599A2 Chemokine receptor binding heterocyclic compounds |
| 03/21/2002 | WO2002022595A1 N-substituted benzothiophenesulfonamide derivatives |
| 03/21/2002 | WO2002022592A2 Substituted urea neuropeptide y y5 receptor antagonists |
| 03/21/2002 | WO2002022588A1 Novel pyrimidine derivative and novel pyridine derivative |
| 03/21/2002 | WO2002022573A2 Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies |
| 03/21/2002 | WO2002022572A2 Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission) |
| 03/21/2002 | WO2002022571A2 Compounds and methods for inhibiting alpha-1 beta-1 integrins |
| 03/21/2002 | WO2002022562A1 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | WO2002022561A1 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | WO2002022558A2 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | WO2002022212A2 Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| 03/21/2002 | WO2002022211A2 Reduction of the electrocardiographic ot interval |
| 03/21/2002 | WO2002022177A2 High efficiency cardiac gene transfer |
| 03/21/2002 | WO2002022176A1 Method of modulating neovascularization |
| 03/21/2002 | WO2002022166A2 Tweak receptor agonists as anti-angiogenic agents |
| 03/21/2002 | WO2002022163A1 Remedies for ischemic diseases |
| 03/21/2002 | WO2002022161A2 The diagnosis, prevention, and/or treatment of atherosclerosis and underlying and/or related diseases |
| 03/21/2002 | WO2002022160A2 The diagnosis, prevention, amelioration and/or treatment of disturbed immune function induced by disturbed lipid metabolism |
| 03/21/2002 | WO2002022152A2 Use of deltorphin a and/or dermorphin h for protection against ischemia and reperfusion injury |
| 03/21/2002 | WO2002022151A2 Use of glp-1 and flp-2 peptides for treatment of bone disorders |
| 03/21/2002 | WO2002022143A1 A pharmaceutical composition for treating headache disease and process and uses thereof |
| 03/21/2002 | WO2002022141A2 Xenon as medicament |
| 03/21/2002 | WO2002022135A1 Creatine ester pronutrient compounds and formulations |
| 03/21/2002 | WO2002022134A1 Use of arginine in the preparation of a medicament for the prevention and treatment of the side effects associated with the intravenous administration of pharmaceuticals |
| 03/21/2002 | WO2002022123A1 Alpha v integrin receptor antagonists |
| 03/21/2002 | WO2002022113A2 Retinoic acid receptor antagonists as promoters of angiogenesis |
| 03/21/2002 | WO2002022112A2 Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production |
| 03/21/2002 | WO2002022111A2 Combination of lipoic acids and conjugated acids for treating diabetic disorders |
| 03/21/2002 | WO2002022074A2 Use of 2- and 4- quinolones for inhibiting intimal neo-proliferation |
| 03/21/2002 | WO2002021934A1 Use of carnitine for enhancing training-induced bradycardia |
| 03/21/2002 | WO2001098324A8 Peptide conjugates modified n- and/or c-terminally by short charged peptide chains |
| 03/21/2002 | WO2001087846A3 Tricyclic pyrazole derivatives as protein kinase inhibitors |
| 03/21/2002 | WO2001081346A3 Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| 03/21/2002 | WO2001078529A3 Compositions and methods for improving vascular health |
| 03/21/2002 | WO2001077376A8 Diagnosis of diseases associated with metastasis |
| 03/21/2002 | WO2001077164A8 Diagnosis of diseases associated with apoptosis by means of assessing the methylation status of genes associated with apoptosis |
| 03/21/2002 | WO2001074902A3 Adenine binding g protein coupled receptors |
| 03/21/2002 | WO2001074379A3 Methods for inducing angiogenesis using morphogenic proteins and stimulatory factors |
| 03/21/2002 | WO2001070694A8 Amorphous torasemide modification |
| 03/21/2002 | WO2001068859A3 Il-17 receptor like molecules and uses thereof |
| 03/21/2002 | WO2001068568A3 Il-8 receptor antagonists |
| 03/21/2002 | WO2001068074A3 Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds |
| 03/21/2002 | WO2001066099A3 Use of quinazoline derivatives as angiogenesis inhibitors |
| 03/21/2002 | WO2001064837A3 β NETRIN AND USES THEREOF |
| 03/21/2002 | WO2001064715A3 Memno peptides, a process for their preparation and their use |
| 03/21/2002 | WO2001064165A3 Il-8 receptor antagonists |
| 03/21/2002 | WO2001062942A3 MATERIALS AND METHODS INVOLVING HYBRID VASCULAR ENDOTHELIAL GROWTH FACTOR DNAs AND PROTEINS AND SCREENING METHODS FOR MODULATORS |
| 03/21/2002 | WO2001062905A3 Integrin antagonists |
| 03/21/2002 | WO2001060991A3 Human kinases |
| 03/21/2002 | WO2001058954A3 Trade molecules and uses related thereto |
| 03/21/2002 | WO2001055106A3 Novel melanocortin receptor agonists and antagonists |
| 03/21/2002 | WO2001051638A3 Drug metabolizing enzymes |
| 03/21/2002 | WO2001041754A3 Inhibitors of collagen-induced platelet aggregation |
| 03/21/2002 | WO2001035943A3 Dextrose and insulin fluid formulation for intravenous infusion |
| 03/21/2002 | WO2001034196A3 Mixture containing rare earths and use thereof |
| 03/21/2002 | WO2001034136A3 Use of adatanserin for the treatment of neurodegenerative conditions |
| 03/21/2002 | WO2001014372A3 Oxazole and thiazole derivatives as neurotrophin production/secretion promoting agent |
| 03/21/2002 | WO2001003774A3 Pharmaceutical composition for the treatment of calcification |
| 03/21/2002 | US20020035737 Cloning pigs using donor nuclei from differentiated cells |
| 03/21/2002 | US20020035735 Reproducing and animal; obtain preferential embryonic cells, culture cells, transfer cells to primate, recover infant |
| 03/21/2002 | US20020035394 Methods and apparatus for stenting comprising enhanced embolic protection, coupled with improved protection against restenosis and thrombus formation |
| 03/21/2002 | US20020035386 Therapeutic light source and method |
| 03/21/2002 | US20020035262 7-hetero-bicyclo[2.2.1]-heptanes |
| 03/21/2002 | US20020035140 1-(pyrrlolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
| 03/21/2002 | US20020035135 Oral administering; storage stability |
| 03/21/2002 | US20020035125 Therapeutic combination |
| 03/21/2002 | US20020035122 8-azabicyclo[3.2.1]oct-2-ene and -octane derivatives |
| 03/21/2002 | US20020035117 Theophylline and 3-isobutyl-1-methylxanthine based N-7 substituted derivatives displaying inhibitory activities on type five phosphodiesterase |
| 03/21/2002 | US20020035114 Substituted dimeric compounds |
| 03/21/2002 | US20020035110 Treatment or prevention of disorders of the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, and sleep apnea |
| 03/21/2002 | US20020035102 Azetidine derivatives, their preparation and medicaments containing them |
| 03/21/2002 | US20020035094 Substituted pyridine compounds and methods of use |
| 03/21/2002 | US20020035092 Propanoic acid derivatives |
| 03/21/2002 | US20020035064 Method for treating atherosclerosis employing an aP2 inhibitor and combination |
| 03/21/2002 | US20020034803 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 03/21/2002 | US20020034787 Nucleotide sequences coding polypeptides for use in treatment of wounds, burns, ulcers, nervous system disorders and tumors |
| 03/21/2002 | US20020034779 Novel argS |
| 03/21/2002 | US20020034777 Modulator of use in the diagnosis, prevention and treatment of inflammation, cancer and nervous system disorders; hypotensive agent |
| 03/21/2002 | US20020034764 Diarylsulfonylurea binding proteins |
| 03/21/2002 | US20020034736 Nucleotide sequences coding modulators for use in therapy against tumors, retinopathy, perfusion injuries, fibrosis, artherosclerosis, angiogenesis, inflammation, and restenosis; antiischemic and antitumor agents |
| 03/21/2002 | US20020034546 Pharmaceutical composition containing a combination of a statin and aspirin and method |
| 03/21/2002 | US20020034534 Receptor loading dosage form containing therapeutic agent and extended-release dosage form containing therapeutic agent administered concurrently |
| 03/21/2002 | US20020034393 Vector |
| 03/21/2002 | DE10045059A1 Therapeutische Kombination von Liponsäure und Konjuensäuren zur Behandlung diabetischer Störungen The therapeutic combination of lipoic acid and conjugated fatty acids for the treatment of diabetic disorders |
| 03/21/2002 | DE10044325A1 Neue MMP-2-Derivate als Inhibitoren des Integrins avbeta3 New MMP-2 derivatives as inhibitors of the integrin avbeta3 |
| 03/21/2002 | CA2432780A1 Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin f25g(a) antagonists |
| 03/21/2002 | CA2422586A1 Methods and compositions relating to hydrogen peroxide and superoxide production by antibodies |
| 03/21/2002 | CA2422376A1 Isoxazoles and their use as inhibitors of erk |
| 03/21/2002 | CA2422288A1 Novel mammalian receptor genes and uses |
| 03/21/2002 | CA2422233A1 Interphenylene 7-oxabicyclic[2.2.1]heptane oxazoles as prostaglandin f2aantagonists |
| 03/21/2002 | CA2422163A1 Isolated human kinase proteins, nucleic acid molecules and uses thereof |
| 03/21/2002 | CA2422095A1 Tweak receptor agonists as anti-angiogenic agents |
| 03/21/2002 | CA2422076A1 Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| 03/21/2002 | CA2422055A1 Ligands for monoamine receptors and transporters, and methods of use thereof (neurotransmission) |
| 03/21/2002 | CA2422032A1 The diagnosis, prevention, amelioration and/or treatment of disturbed immune function induced by disturbed lipid metabolism |
| 03/21/2002 | CA2422026A1 Reduction of the electrocardiographic qt interval for reducing the risk of sudden death |
| 03/21/2002 | CA2422013A1 Substituted urea neuropeptide y y5 receptor antagonists |
| 03/21/2002 | CA2421994A1 The diagnosis, prevention, and/or treatment of atherosclerosis and underlying and/or related diseases |
| 03/21/2002 | CA2421966A1 Remedies for ischemic diseases |
| 03/21/2002 | CA2421920A1 Use of arginine in the preparation of a medicament for the prevention and treatment of the side effects associated with the intravenous administration of pharmaceuticals |